37.52
price up icon0.21%   0.08
after-market アフターアワーズ: 37.56 0.04 +0.11%
loading

Novo Nordisk Adr (NVO) 最新ニュース

pulisher
Apr 11, 2026

Novo Nordisk Leans Into Obesity Care With ORION Data And Wegovy Pricing - Sahm

Apr 11, 2026
pulisher
Apr 10, 2026

NVO Stock Quote Price and Forecast - CNN

Apr 10, 2026
pulisher
Apr 10, 2026

NVO Forecast, Price Target & Analyst Ratings | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill

Apr 10, 2026
pulisher
Apr 09, 2026

Eli Lilly Faces Pressure In India As Cheaper GLP-1 Rivals Dent Mounjaro Sales - Benzinga

Apr 09, 2026
pulisher
Apr 09, 2026

Novo Nordisk Wins EU Nod To Ease Wegovy Injection Delivery - Sahm

Apr 09, 2026
pulisher
Apr 08, 2026

Novo Nordisk A/ S stock: Why it's still a powerhouse amid volatility - AD HOC NEWS

Apr 08, 2026
pulisher
Apr 08, 2026

NVO News | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill

Apr 08, 2026
pulisher
Apr 07, 2026

Novo Nordisk (NYSE: NVO) details progress in DKK 15B buyback - Stock Titan

Apr 07, 2026
pulisher
Apr 06, 2026

Novo Nordisk A/ S stock: Weight-loss boom far from over — what investors need to know - AD HOC NEWS

Apr 06, 2026
pulisher
Apr 04, 2026

Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 04, 2026
pulisher
Apr 04, 2026

Novo Nordisk Wegovy Subscription Targets Self Pay Demand And Investor Focus - Sahm

Apr 04, 2026
pulisher
Apr 02, 2026

NVO Stock Chart | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill

Apr 02, 2026
pulisher
Apr 01, 2026

Novo Nordisk A/S Stock: Navigating GLP-1 Leadership Amid Evolving Obesity Treatment Landscape - AD HOC NEWS

Apr 01, 2026
pulisher
Mar 31, 2026

Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan - Sahm

Mar 31, 2026
pulisher
Mar 30, 2026

Novo Nordisk (NYSE: NVO) details progress on DKK 15bn share repurchase - Stock Titan

Mar 30, 2026
pulisher
Mar 30, 2026

Novo Nordisk A/S Stock: Pipeline Innovations Amid Share Price Pressures and Market Challenges - AD HOC NEWS

Mar 30, 2026
pulisher
Mar 29, 2026

Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program - Sahm

Mar 29, 2026
pulisher
Mar 28, 2026

Novo Nordisk A/S Stock: FDA Approval for Awiqli Bolsters Diabetes Portfolio Amid 2026 Market Recover - AD HOC NEWS

Mar 28, 2026
pulisher
Mar 27, 2026

Novo Nordisk A/S Stock: Recent AGM Resolutions Reinforce Dual-Class Structure and Dividend Strength - AD HOC NEWS

Mar 27, 2026
pulisher
Mar 25, 2026

Novo Nordisk A/S stock faces pressure amid shifting obesity drug landscape and analyst hold rating - AD HOC NEWS

Mar 25, 2026
pulisher
Mar 24, 2026

Novo Nordisk A/S stock faces analyst scrutiny amid Wegovy demand questions and Equal Weight rating h - AD HOC NEWS

Mar 24, 2026
pulisher
Mar 22, 2026

Novo Nordisk A/S stock faces FDA warnings on GLP-1 drugs amid rising competition pressures - AD HOC NEWS

Mar 22, 2026
pulisher
Mar 20, 2026

NVO Price History for Novo Nordisk A/S ADR Stock - Barchart.com

Mar 20, 2026
pulisher
Mar 19, 2026

Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy - Sahm

Mar 19, 2026
pulisher
Mar 18, 2026

Novo Nordisk A/S stock faces pressure from FDA warning on semaglutide reporting and Bernstein Underp - AD HOC NEWS

Mar 18, 2026
pulisher
Mar 18, 2026

Novo Nordisk A/S stock faces headwinds from CagriSema trial setback amid buyback progress and compet - AD HOC NEWS

Mar 18, 2026
pulisher
Mar 17, 2026

Novo Nordisk A/S stock rebounds on UBT251 trial data amid CEO turmoil and buyback momentum - AD HOC NEWS

Mar 17, 2026
pulisher
Mar 16, 2026

Novo Nordisk A/S - GlobeNewswire Inc.

Mar 16, 2026
pulisher
Mar 16, 2026

Novo Nordisk A/S Stock (ISIN: DK0062498333) Faces Headwinds from FDA Warning Amid GLP-1 Demand - AD HOC NEWS

Mar 16, 2026
pulisher
Mar 15, 2026

Novo Nordisk A/S Stock Faces Brutal Choice: Can Oral Wegovy Rescue the Semaglutide Empire? - AD HOC NEWS

Mar 15, 2026
pulisher
Mar 14, 2026

FDA Warning Tests Novo Nordisk Compliance And Reshapes NYSE NVO Risk Profile - Sahm

Mar 14, 2026
pulisher
Mar 14, 2026

Novo Nordisk Telehealth Deal Weighs On Weak Share Price And Valuation - sahmcapital.com

Mar 14, 2026
pulisher
Mar 12, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - Finansavisen

Mar 12, 2026
$138.99
price down icon 2.18%
PFE PFE
$26.92
price down icon 1.10%
$351.02
price down icon 1.29%
NVS NVS
$154.05
price down icon 0.65%
MRK MRK
$121.42
price down icon 1.03%
大文字化:     |  ボリューム (24 時間):